Late-stage functionalization with strain-release warheads enables tunable covalent inhibition
Science · 23.07.2026 · 393 (6809) · 408-416
DOI: 10.1126/science.adx7219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 23.07.2026. Verfasst von Zachary P Shultz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Cysteine, Drug Design, Proteins, Sulfur. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration–approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Department of Chemistry, University of South Florida, Tampa, FL, USA.
- Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Cancer Pharmacokinetics and Pharmacodynamics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, FL, USA.
ORCID-Profile: Zachary P Shultz, Ansar Lee-Sam, Yun-Pu Chang, Luxin Sun, Dylan Grassie, Kyle Pedretty, Thomas Scattolin, Victoria Izumi, Bin Fang, Samer Sansil, Ramu Kakumanu, Lukasz Wojtas, John Koomen, Ernst Schönbrunn, Andrii Monastyrskyi, Derek Duckett, Justin M Lopchuk
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institute of General Medical Sciences
Zitieren
APA
Shultz, Z. P., Lee-Sam, A., Chang, Y. P., Sun, L., Grassie, D., Gabellini, A., Pedretty, K., Scattolin, T., Izumi, V., Fang, B., Sansil, S., Kakumanu, R., Wojtas, L., Koomen, J., Schönbrunn, E., Monastyrskyi, A., Duckett, D., & Lopchuk, J. M. (2026). Late-stage functionalization with strain-release warheads enables tunable covalent inhibition. Science, 393(6809), 408-416. https://doi.org/10.1126/science.adx7219
Vancouver
Shultz ZP, Lee-Sam A, Chang YP, Sun L, Grassie D, Gabellini A, et al. Late-stage functionalization with strain-release warheads enables tunable covalent inhibition. Science. 2026;393(6809):408-416. doi:10.1126/science.adx7219
BibTeX
@article{Shultz2026,
author = {Shultz, Zachary P and Lee-Sam, Ansar and Chang, Yun-Pu and Sun, Luxin and Grassie, Dylan and Gabellini, Alessio and Pedretty, Kyle and Scattolin, Thomas and Izumi, Victoria and Fang, Bin and Sansil, Samer and Kakumanu, Ramu and Wojtas, Lukasz and Koomen, John and Schönbrunn, Ernst and Monastyrskyi, Andrii and Duckett, Derek and Lopchuk, Justin M},
title = {Late-stage functionalization with strain-release warheads enables tunable covalent inhibition},
journal = {Science},
year = {2026},
volume = {393},
number = {6809},
pages = {408--416},
doi = {10.1126/science.adx7219}
}
EUVIMED